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It was stated years ago that physicians pour 
medicines about which they know little, for diseases 
about which they know less, into human beings about 
whom they know nothing.' Although as a prophet 
this wag may have overstated the case as it concerns 
the therapy of urinary tract infections (UTI), the 
character of contemporary infectious diseases is, in 
part, due to the use and abuse of anti-infective 
agents. 2•3 One has only to look at the rising incidence 
of gram-negative bacteremia and the emergence of 
multiple antibiotic-resistant organisms over the past 
several decades to appreciate the impact physicians 
have made with these agents.4· 5 Despite the draw-
backs, the benefits resulting from the use of antibiot-
ics far outweigh the deleterious effects, a fact perhaps 
realized most vividly by physicians whose careers 
reach back to the pre-chemotherapeutic era. The en-
thusiasm for antibiotics makes them one of the most 
prescribed groups of drugs in the United States, ac-
counting for 15% to 20% of all new and refill pre-
scriptions.6 Undoubtedly many of the prescriptions 
are used to treat persons with UTis, in light of the 
fact that UTls are said to rank second only to upper 
respiratory infections as the most common infections 
in the western hemisphere.7 
Principles of Therapy 
Without belaboring the point, how does the phy-
sician steer his way through the many antibiotics 
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which are promoted so vigorously by pharmaceutical 
companies, perhaps in response to the competitive 
pressures and potential profits of what has become a 
multi-billion dollar industry? Certain characteristics 
are desirable in any antibiotic, and it behooves the 
physician to consider these characteristics when eval-
uating the potential usefulness of the agent.8 
I. Activity. An agent with bactericidal activity 
against a wide spectrum of microorganisms, and one 
that doesn't disturb normal flora or lead to the emer-
gence of resistant organisms should be sought. 
2. Toxicity. Adverse reactions should be infre-
quent, and teratogenicity absent. 
3. Pharmacology. Pharmacologic properties should 
be such that adequate concentrations of the drug are 
achieved and maintained near the organism for pro-
longed periods. 
4. Physicochemica/ properties. The drug should 
be stable ( dry or in solution) tolerant of pH changes, 
and readily absorbable from the gastrointestinal (GI) 
tract. 
5. Interactions . The drug should not interact with 
other therapeutic agents. 
6. Cost. The agent should be inexpensive and 
hence available to all who need it. 
Of course, no such "magic bullet" exists, and 
because it doesn't , one should be guided, when treat-
ing UTis, by certain fundamental principles.9 
I . The presence of a bacterial infection should be 
established. Symptoms alone are not sufficient evi-
dence for the diagnosis of UTI, as up to 50% of 
women with dysuri a and frequency have sterile 
urine.10 The finding of one or more bacteria per oil 
field in a Gram stain of uncentrifuged urine correlates 
69 
70 MARKOWITZ: THERAPY FOR URINARY TRACT INFECTIONS 
well ( over 90%) with the presence of 100,000 orga-
nisms or more per ml of urine. Numbers of this 
magnitude usually indicate true infection (significant 
bacteriuria) and not procurement contamination 
with gram-negative enteric bacilli. In an asympto-
matic person, three consecutive daily urine cultures 
obtained by the clean-voided method and each con-
taining 100,000 organisms per ml of the same bacte-
rium indicate that the patient has at least a 95% 
chance of having a UTI.11 In a symptomatic person, 
bacteria seen on microscopic examination and one 
urine culture containing 100,000 organisms or more 
per ml carries the same 95% probability of true in-
fection. 
2. The elimination of bacteriuria requires the use 
of antibiotics which are active against the common 
urinary pathogens and which achieve inhibitory con-
centrations in the urine, not the serum. Dis-
appearance of bacteriuria correlates well with the 
sensitivity of the organism to achievable urinary lev-
els.12·18 This serves to underline the obvious dis-
crepancies sometimes seen between antibiotic sensi-
tivities in vitro and the eradication of bacteriuria. 
3. Underlying urinary tract abnormalities, par-
ticularly obstructive or neurogenic lesions, should be 
corrected if possible; obstruction from whatever 
cause not only has a compromising effect on renal 
function but it also practically eliminates the likeli-
hood of successful antibiotic therapy. 
4. The hallmark for the eradication of infection 
is the absence of bacteriuria following the cessation 
of therapy. Symptomatic improvement is a poor in-
dicator of successful therapy because symptoms may 
improve with only the slightest suppression of bacte-
riuria. In addition, while bacteriuria may disappear 
during therapy, recurrence of the original organism 
(see below) is common and can be detected only by 
obtaining cultures after the completion of therapy. 
5. Prolonged follow-up is required to insure per-
manent cure of the UT!. Recurrence of an initially 
symptomatic and apparently successfully treated in-
fection may be asymptomatic, and constant vigilance 
by the physician can pay dividends in reduced mor-
bidity from UT!s. This is done usually by obtaining 
periodic urine cultures (Figure). A culture obtained 
between 48 to 72 hours after the initiation of therapy 
should be sterile. If it is not, then the therapy should 
be recognized as a failure and the patient should be 
treated with an appropriate antibiotic chosen on the 
basis of sensitivity tests. If the culture is negative, 
additional cultures should be obtained one to two 
weeks following completion of therapy, monthly for 
three months, then at three-month intervals for one 
to I V2 years. The patient should be considered cured 
if there is no recurrence during the period of observa-
tion. 
Therapeutic Agents 
The goal of therapy for UT!s is the elimination 
of bacteriuria and the most effective way of achieving 
this is with antibiotic therapy. The antimicrobial 
agents frequently used to treat UT!s are listed in the 
Table. Most share the common characteristics of 
being active against the majority of common urinary 
tract pathogens and being excreted at high concentra-
tions into the urine. 
Sulfonamides. The sulfonamides were the first 
group of agents shown to be consistently useful for 
treating UT!s. Many effective sulfonamides are avail-
able, but the short-acting, oral nonabsorbable drugs, 
such as sulfisoxazole and sulfamethoxazole, are gen-
erally recommended. These agents achieve high uri-
nary concentrations and are soluble at an acid pH. 
Toxicity is relatively infrequent. They are especially 
effective against Escherichia coli and Proteus mirabilis 
but generally are useful only for the first few episodes 
of infection because of the emergence of resistant 
bacteria. Although sulfonamides offer no real advan-
tage over other agents, they are inexpensive (see 
Table) and hence available to most patients. Sulfona-
mides should not be used in persons with glucose-6-
phosphate dehydrogenase deficiency, in pregnant 
women near term, and in newborn infants because of 
the danger of producing kernicterus in the neonate. 
Penicillins. Among the penicillins, ampicillin re-
mains the drug of choice for UT!s. It is effective 
against many gram-positive and gram-negative orga-
nisms and reaches adequate levels in the renal me-
dulla. Ampicillin is the preferred agent for pregnant 
women and newborns, and is especially useful in 
treating UT!s due to susceptible organisms in pa-
tients .with renal insufficiency. There is no evidence to 
indicate that ampicillin is superior to sulfonamides in 
the management of uncomplicated UT!s (see below), 
just as there is no evidence to indicate that newer 
penicillin derivatives, such as amoxicillin, are supe-
rior to ampicillin. Diarrhea is frequent and rashes 
occur in 5% to 10% of patients.1 
Tetracyclines. The tetracyclines have been rele-
gated to a less prominent role in the treatment of 
UT!s. The best urinary levels are achieved with tet-
racycline and oxytetracycline.11 Newer derivatives, 
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Acute 
Symptoms* 
! 
culture urine and 
begin therapy 
Reinfection 
l 
Culture urine 
+ 
Asymptomatic 
bacteriuria* 
! 
2 consecutive cultures 
with same organism 
precedes therapy 
If bacteriological and/or 
clinical response, treat 
for 10-14 days 
Relapse 
~ 
Negative 
cultures 
Retreat with appropriate Consider therapy l drug 10-14 days for 6 weeks 
CURE 
If frequent, 
consider long 
term prophylaxist 
Reinfection 
If occassional treat 
each episode for 
10-14 days 
Relapse 
l 
Consider therapy 
for 6-12 months 
CURE 
CURE 
* Radiographic evaluation should be obtained on all children, 
all men, young women, and probably in all patients with 
bacteremia 
t Not in asymptomatic elderly without obstruction 
Figure-Diagrammatic approach to the management of urinary tract infections. 
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TABLE 
Antibiotics Useful in the Therapy of Urinary Tract Infections in Adults 
Antibiotic Tradename(s) 
Oral: 
Sulfisoxazole Gantrisin 
Sulfamethoxazole G antanol 
Penicillin G Many 
Ampicillin Many 
Amoxicillin Larotid , Amoxil 
Tetracycline Many 
Cephradine Velosef, Anspor 
Cephalexin Ke flex 
Nitrofurantoin Furadantin 
Macrodantin 
Nalidixic acid NegGram 
Trimethoprim-Sulfamethoxazole Bactrim , Septra 
Parenteral: 
Ampicillin Many 
Carbenicillin Geopen , Pyopen 
Cephalothin Keflin 
Cefazolin Ancef, Kefzol 
Gentamicin Garamycin 
Amikacin Ami kin 
Dosage• 
0 .5-1.0 gm q 4-6 h 
I.Ogm q 8-12 h 
0.4-0.8 X I 0'µ q 6 h 
0.5-1.0 gm q 6 h 
0.25-0.5 gm q 8 h 
0.25-0.5 gm q 6 h 
0.5gm q 6 h 
0.5gm q 6 h 
0.05-0. 1 gm q 6 h 
0.05-0.1 gm q 6 h 
0 :5-1.0 gm q 6 h 
2 tablets q 12 h 
0.5-2 gm q 4-6 h 
1-5 gm q 4-6 h 
0.5-2 gm q 4-6 h 
0.5-1.5 gm q 6-8 h 
1-1.7 mg/ kg q 8 h 
5 mg/ kg q 8 h 
Cost in dollars (dose)b 
.04 (0 .5 gm) 
.08 (0.5 gm) 
.01 (0.2 X IO'µ) 
.09 (0.5 gm) 
.30(0.5gm) 
.03 (0.5 gm) 
.56 (0.5 gm) 
.52 (0.5 gm) 
.01 (0.05 gm) 
.15(0.05gm) 
.12 (0.5 gm) 
.21 (per ta blet) 
1.11 (I gm) 
2.20(1 gm) 
2.75 (I gm) 
5.05 (I gm) 
5.05 (per 80 mg vial) 
4 .93 (per 100 mg) 
• Usual average or range of dosages in patients with normal renal function. 
b Cost to pharmacist based on listings in the American Druggist Blue Book (Hearst Corp. Publishers), October 1977. 
such as doxycycline and minocycline, although ap-
proved for use in UTis, have significant extrarenal 
routes of excretion, so that the low urinary concen-
tration achieved makes them Jess desirable for ther-
apy.14 Generic tetracycline is inexpensive (see Table). 
Resistance to tetracycline emerges rapidly during 
therapy; however, tetracyclines are probably as effec-
tive as the· sulfonamides and ampicillin for treating 
uncomplicated UTis (see below). Fulminant hepatitis 
has been induced in those receiving large parenteral 
doses of tetracycline (greater than 2 gm per day), and 
irreversible discoloration and maldevelopment of 
permanent teeth is a danger in children under age 8 
who receive these drugs 14; however, GI signs and 
symptoms are the most common side effects of ther-
apy. u 
Cephalosporins. The instances where ceph-
alosporin antibiotics should be used are difficult to 
define, but they are indicated possibly for treating 
gram-positive coccal infections (except those caused 
by enterococci and methicillin-resistant staphylo-
cocci) in patients a llergic to penicillin. These agents 
are useful in treating infections due to Klebsiella 
pneumoniae and antibiotic strains of E coli, P mira-
bilis, and other gram-negative bacilli . The use of 
cephalosporin antibiotics for central nervous system 
infections is contraindicated.15 Although most of 
these drugs achieve good urinary levels, and are 
therefore effective agents for the therapy of UTis, 
most are expensive (see Table) and should not be 
used when cheaper, equally effective drugs are avail-
able. The two most important oral agents, cephalexin 
and cephradine, are similar and can be used inter-
changeably.16 Up to 5% of patients develop allergic 
reactions such as rash , fever, and, rarely, anaphy-
Jaxis11; 5% to 15% of penicillin-allergic patients will 
manifest allergy to the cephalosporins. 18 
Aminoglycosides. The aminoglycoside antibiotics 
are parenterally administered agents useful against a 
wide variety of gram-negative organisms. These 
drugs have the potential for causing significant oto-
and nephrotoxicity1• and should therefore be reserved 
for therapy of hospitalized patients with moderate to 
severe UTis caused by organisms resistant to Jess 
toxic agents. Dosage should be adjusted for those 
with renal insufficiency; such a lterations in dosage 
can be achieved by any of several published pro-
grams.20- 22 Gentamicin and amikacin are two com-
monly used aminoglycoside antibiotics which differ 
little in the incidence of toxicity.23 However, amikacin 
is resistant to many more of the aminoglycoside-
inactivating enzymes than gentamicin,24 therefore its 
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greatest utility at present is in the therapy of UTis 
caused by gentamicin-resistant organisms. 
Nitrofurantoin. This drug is available in crystal-
line and macrocrystalline forms. The latter com-
pound is absorbed from the GI tract and excreted 
more slowly than the crystalline form and allegedly 
causes less GI upset. Nitrofurantoin achieves high 
urine concentrations and is more active at an acid 
pH . It is effective against gram-positive and gram-
negative organisms except Pseudomonas sp, some En-
terobacter sp, Serratia marcescens, and indole-posi-
tive Proteus. The drug may be useful for lower and 
upper UTI. 11 Nitrofurantoin is contraindicated for 
use in patients with renal failure because little of the 
drug is found in the urine and because the incidence 
of irreversible peripheral neuropathy is increased un-
der these circumstances. 11 Small amounts of this 
orally administered drug is found in the feces, which 
probably accounts for the relatively low incidence of 
resistant enteric organisms emerging during and after 
therapy. Thus, nitrofurantoin would appear to be a 
useful therapeutic and prophylactic agent for patients 
with recurrent UT1s25 (see below). 
Nalidixic acid. N alidixic acid and its co gen er, 
oxolinic acid, are oral antimicrobials which have vir-
tually the same antibacterial spectrum, including 
most gram-negative urinary tract pathogens except 
for Pseudomonas sp, Serratia marcescens and indole-
positive Proteus. Resistance develops rapidly and re-
currence of infection with resistant organisms is not 
uncommon. Blood and, presumably, tissue levels 
are low. These agents are moderately expensive (see 
Table) and should be used as alternative therapy to 
other oral agents such as the sulfonamides and ampi-
cillin. 
Methenamine salts. Methenamine salts have a 
limited role in the therapy of UTis. These agents are 
effective against most gram-negative organisms in 
vitro, but require an acid medium (pH of 6 or less) 
for release from methenamine of the bactericidal 
agent formaldehyde; tissue levels are low to absent. 
The main uses are for suppression of bacteriuria or 
prophylaxis between episodes of infection. The effi-
cacy of methenamine salts in patients with chronic in-
dwelling bladder catheters recently has been ques-
tioned.26 
Trimethoprim-sulfamethoxazole (TM P-SM X ). 
TMP-SMX is a fixed combination of drugs which 
acts additively or synergistically against a wide range 
of gram-positive (including enterococci) and gram-
negative organisms, except Pseudomonas and Alcali-
genes sp . The list of indications for TMP-SMX con-
tinues to grow and presently includes infections due 
to Shigella sp, Salmonella typhi, ampicillin-resistant 
Haemophilus infiuenzae, and Pneumocystis carinii, 
and diseases such as acute exacerbations of chronic 
bronchitis, acute otitis media, and gonococcal ure-
thritis.27 Its most practical applications are the treat-
ment of and prophylaxis for recurrent UTis caused 
by susceptible organisms.25 Emergence of resistant 
organisms in the fecal flora has not been a major 
problem and because trimethoprim penetrates pros-
tatic tissue, TMP-SMX is probably the drug of choice 
for recurrent or chronic prostatic infection.28 The 
adverse effects of TMP-SMX represent the sum of 
reactions to trimethoprim (folate deficiency syn-
dromes and possible teratogenic effects) and sulfame-
thoxazole (see above) . The drug may be used in mild-
to-moderate renal failure. 29 
Urinary Tract Infections 
Urinary tract infections represent a broad group 
of clinical entities with bacteriuria as the common 
thread . Many classifications are possible, but those 
which include not only the type of infection but also 
the site of involvement allow for the most accurate 
assessment of antibiotic therapy. Although the site of 
infection in many instances is unknown, enough evi-
dence is available to analyze antibiotic therapy in the 
following clinical categories of UTI: acute uncompli-
cated UTI; recurrent UTI ; complicated UTI; asymp-
tomatic bacteriuria; and catheter-related UTI. 
A cute uncomplicated UT/s usually represent the 
first or second infection in young sexually active 
women without underlying urinary tract abnormal-
ities, and are caused by antibiotic enteric bacilli (most 
commonly E coli) which emanate from antibiotic 
fecal flora . This type of infection responds well to 
practically all commonly used oral antibiotics, but 
because they are effective, inexpensive, and well-tol-
erated, the oral, nonabsorbable sulfonamides remain 
the therapy of choice. Treatment is usually given for 7 
to 14 days . Longer courses of therapy are usually not 
necessary. Many alternative agents exist (see Table), 
but none have proven superior to the sulfonamides 
and most are more expensive. In the absence of an 
obstructive or neurogenic lesion , the urine should be 
sterile between 48 to 72 hours (Figure). If bacteriuria 
persists, therapy should be guided by the results of 
sensitivity testing. 
Some patients with acute symptomatic infection 
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fail to respond to the initial antibiotic therapy or 
suffer recurrence of the infection. The recurrence may 
be a relapse of the initial infection with the same 
pathogen, suggesting a parenchymal focus of infec-
tion in the kidney or prostate or may be caused by 
different organisms, so-called reinfections. The source 
for reinfection is almost always the bowel flora. Ap-
proximately 80% of recurrences are reinfections and 
most are limited to the bladder. Antibiotic sensitivity 
testing assumes added importance in this situation 
because the pathogen will probably not be sensitive 
to sulfonamides if used initially. Ampicillin, tetracy-
clines, cephalosporins, and TMP-SMX are preferred 
and are given orally for IO to 14 days. Each course of 
therapy will result in a 20% to 25% long-term cure 
rate. 11 Those having a second or third episode of 
infection should probably be evaluated urologically 
or radiographically (see Figure) . Those with occa-
sional recurrences ( three or less per year) can be 
treated like acute uncomplicated infection. With 
more frequent recurrences, especially in the absence 
of urological abnormalities, the precise duration of 
therapy is not well established . Closely spaced recur-
rences are likely to be due to relapse and some have 
suggested treating true relapses for six weeks to one 
year. 10 Most authorities suggest six weeks of therapy 
with the realization that the optimal duration of ther-
apy for this group of patients is controversial. An 
alternative approach consists of intensive initia l treat-
ment for 10 to 14 days, followed by daily low-dose 
nitrofurantoin (100 mg) or TMP-SMX (one half to 
one tablet). Prophylaxis should be continued for up 
to six months, then discontinued, and the patient 
observed. 
A cute complicated UT ls are a third category of 
infections; they are almost always associated with 
underlying genitourinary tract or neurological dis-
orders. Isolated organisms tend to be multiply 
drug-resistant. Permanent eradication of the bac-
teriuria is unlikely, but the goal is to control symp-
toms. Initial therapy ideally should be based on 
sensitivity studies, but pending culture results, an 
aminoglycoside antibiotic, that is, gentamicin, is an 
obvious choice. Therapy for IO to 14 days is usually 
adequate. Emergence of resistant organisms in this 
setting is a probable event. 
Asymptomatic bacteriuria represents a large 
group of UTis with an incidence ranging from 1.2% 
in pre-school girls to over 15% in women over age 
60. 11 Certain groups are known to be at risk for 
acquiring significant asymptomatic bacteriuria and 
subsequent symptomatic UTI. Included are pregnant 
women in the first trimester, women with diabetes, 
preschool- and school-age girls, and those with a 
previous history of urinary tract instrumentation . 
About 5% of pregnant women will have asympto-
matic bacteriuria at the first prenatal visit and 20% to 
40% of these will develop acute pyelonephritis.9 As-
suming that acute renal infection in the mother con-
tributes to prematurity and fetal mortality, treatment 
should be initiated. The preferred agents are the pen-
icillins, cephalosporins, nitrofurantoin, and short-
acting sulfonamides (first trimester only). Treatment 
will eliminate bacteriuria in 80% of these patients. 
Some will have recurrence and for these patients, 
nightly prophylaxis through term with nitrofurantoin 
is recommended. The necessity to treat other groups 
of patients with asymptomatic bacteriuria is less cer-
tain, especially elderly women in whom bacteriuria 
tends to be recurrent even in the absence of under-
lying disease. Available evidence indicates that, in 
adults, progressive renal damage due to UTI is an 
uncommon occurrence in the absence of obstruc-
tion .10 Several attempts at eradication seem worth-
while. If bacteriuria recurs, genitourinary evaluation 
is warranted. If no abnormalities are found, no fur-
ther therapy is necessary in the elderly. 
Catheter-related infections are the most common 
hospital-acquired infections and the most frequent 
causes of gram-negative bacteremia.•·11 Patients ac-
quiring bacteriuria with short-term closed drainage 
should be treated with an effective antibiotic for 7 to 
10 days after the catheter is removed . Long-term 
drainage represents a different problem. Patients on 
long-term drainage are continuously infected but 
usually do well. Antibiotics will not clear bacteriuria 
permanently while the catheter remains in place. 
Therapy is reserved for acute episodes of infection . 
A scheme for the management of patients with 
bacteriuria is given in the accompanying Figure. It is 
meant to serve only as a guide for the practicing 
physician and should be modified in light of future 
improvements in the diagnosis, localization, and 
therapy of UTis. Optimal therapy awaits a more 
precise classification of UTis, the end result of which 
will be a reduction in morbidity and mortality from 
UTis, and a significant decrease in the cost of related 
health care. 
The figure is reproduced with permission from Urinary Tract 
Infection and Its Management, Donald Kaye (ed). 
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